Lenvima's quarterly sales grow to $106 million; China makes 48-drug list for streamlined review; Samsung commits further investment in biologics.

China's inviting top brands from Lilly, Novartis, GSK and more to go for approval based on foreign clinical trial data.

Samsung BioLogics is slated to get a piece of the $22 billion investment Samsung says it will invest in growth businesses.

The FDA is reporting that the valsartan products may have been on the market for years, not weeks or months.

Multinational pharma companies have all together closed 16 manufacturing plants in South Korea over the past 20 years, local media reports.

The sale gives Dendreon better access to capital for expansion and deals, its top executive said—perhaps into CAR-T or other cell therapies, an area where the…

Shire could fill Takeda's gap of late-stage assets; GSK lays off 1,000 as a Bangladesh plant nears closure; Laekna gets two Novartis cancer drugs.

India’s Wockhardt has built a $40 million manufacturing facility in the Middle East to make drug-resistant antibiotics.